Summary Two hundred and eleven patients with node-positive stage 11 and IlIl breast cancer were treated with eight cycles of adjuvant chemotherapy comprising cyclophosphamide, doxorubicin and oral ftorafur (CAFt), with and without tamoxifen. All patients had undergone radical surgery, and 148 patients were treated with post-operative radiotherapy in two randomized studies. The impact of haematological toxicity of CAFt on distant disease-free (DDFS) and overall survival (OS) was recorded. Dose intensity of all given cycles (Dl), dose intensity of the two initial cycles (Dl2) and total dose (TD) were calculated separately for all chemotherapy drugs and were correlated with DDFS and OS. Patients with a lower leucocyte nadir during the chemotherapy had significantly better DDFS and OS (P = 0.01 and 0.04 respectively). Dose intensity of the two first cycles also correlated significantly with DDFS (P=0.05) in univariate but not in multivariate analysis, while the leucocyte nadir retained its prognostic value. These results indicate that the leucocyte nadir during the adjuvant chemotherapy is a biological marker of chemotherapy efficacy; this presents the possibility of establishing an optimal dose intensity for each patient. The initial dose intensity of adjuvant chemotherapy also seems to be important in assuring the optimal effect of adjuvant chemotherapy.
Dose intensity in chemotherapy is defined as the amount of drug delivered per unit time. In a retrospective study on patients included in a randomized trial of adjuvant chemotherapy on nodepositive breast cancer, Bonadonna and Valagussa (1981) demonstrated a significant correlation between unscheduled dose reduction and reduced survival. Similar results have been published subsequently from many retrospective studies in early and advanced breast cancer (Rodriguez-Kraul et al, 1981; Tormey et al, 1983; Howell et al, 1984; Senn et al, 1984; Ang et al, 1989; Pronzato et al, 1989) , however some retrospective studies have failed to demonstrate any significant correlation between dose and therapy efficacy (Ahmann et al, 1982; Glucksberg et al, 1982; Redmond et al, 1983; Mouridsen et al, 1984; Velez-Garcia et al, 1987) . A series of analyses on published chemotherapy studies demonstrated that a positive correlation existed between the scheduled amount of drug per unit time and the efficacy of chemotherapy treatment on both early and advanced breast cancer (Hryniuk and Bush, 1984; Hryniuk and Levine, 1986) . Only a few controlled prospective studies of the dose-response relationship in breast cancer have been published, and the results have not been consistent. A few studies have demonstrated a survival benefit from receiving a higher dose intensity (Carmo-Pereira et al, 1987; Tannock et al, 1988; Wood et al, 1994) , while many controlled studies have failed to demonstrate any dose-response relationship (Hortobagyi et al, 1987a, b; Ludwig Breast Cancer Study Group, 1985; Walters et al, 1992; Fumoleau et al, 1993) .
The retrospective calculation of dose-intensity has been criticized by Henderson et al (1988) . In retrospective analyses, the correlation between higher dose and better therapy results could result from selection of patients with better tolerance to higher chemotherapy doses. Redmond et al (1983) have published an extensive review on the sources of error in retrospective correlations between dose intensity and outcome. As an illustration of the multiple sources of biases inherent in this kind of analysis, they demonstrated a significant correlation of dose intensity of placebo and outcome in two NSABP trials.
One way to circumvent these biases would be to correlate some biological measurement of dose intensity with treatment outcome. If the positive correlation between dose intensity and outcome were the result of selection bias, one would expect patients experiencing more toxicity to have the worse outcome, while the opposite should be true if the correlation results from a true dose-response effect. Perhaps the most important biological measure of drug effect is the haematological toxicity, which is the dose-limiting toxicity with most chemotherapy schedules.
The purpose of this study was to establish, through retrospective analyses, if a better prognosis was associated with patients having a lower leucocyte nadir (higher biological dose intensity) or with a higher leucocyte nadir (higher dose intensity because of better tolerance of chemotherapy). We also attempted to determine whether dose reductions of doxorubicin-containing adjuvant chemotherapy influenced the DDFS and OS of stage II and III breast cancer patients.
PATIENTS AND METHODS Patients
The study population comprised 211 primary breast cancer patients who were included in two trials conducted simultaneously between 1981 and 1986 in Helsinki University Hospital, Department of Radiotherapy and Oncology. One hundred and forty-nine of the patients had stage II breast cancer and 62 stage III. All patients analyses were performed using the Cox regression technique (Cox, 1972) in EGRET software (SERC, 1988 Of the 211 eligible patients, data from eleven patients were excluded from the analyses because they had not received the planned chemotherapy (five patients refused chemotherapy, four patients were not eligible for doxorubicin based chemotherapy because they were suffering from other severe diseases, one patient was excluded because of a non-radical operation and another because of haematogenous metastases), and a further six were excluded because they received only one cycle of chemotherapy (n=194). In the analyses of prognostic effect of leucocyte, there was one missing value (n=193). In analyses of dose intensity from the two initial cycles of chemotherapy, five patients had missing information on drug doses (n=189), and in analyses of total dose and dose intensity for all cycles, information of cumulative dose was missing in four patients (n=190). Overall dose intensity, total dose and efficacy of haematological toxicity were also analysed by excluding all patients who had received less than four cycles of chemotherapy (n=14) or whose treatment was interrupted because of progression during chemotherapy (n=8). No patients experienced disease progression during the first two cycles of therapy.
RESULTS
Forty-nine patients (26%) discontinued chemotherapy as a result of side-effects, mostly nausea and vomiting. The median number of chemotherapy cycles was seven. Mean total dose of doxorubicin was 240.7 mg m-2 (range 24-400 mg m-2, 86% of the planned total dose. Mean total dose of cyclophosphamide was 2983.5 mg m-2 (range 366-4114 mg m-2), 75% of the planned total dose. Mean dose intensity of doxorubicin was 70% (range 21.6-109.9%) and of cyclophosphamide 70% (range 21.1-100%). Mean dose intensity of doxorubicin during the first two cycles was 82% (39.3-125%), and for cyclophosphamide it was also 82% (42-102.9%). The low level of dose intensity was partly as a result of unscheduled initial dose reductions of approximately 10%, which was later corrected by dose escalation at subsequent courses according to tolerance. Later dose reductions were mostly owing to leucopenia but, in some cases, also because of gastrointestinal side-effects.
In univariate analyses of DDFS and OS in the patients who have received at least two cycles of chemotherapy, a statistically significant correlation between DDFS or OS and the nadir values of leucocytes were established (P = 0.01 and P = 0.04 respectively). Patients with lower leucocyte nadirs had significantly better DDFS and OS than those patients with higher leucocyte nadir.
Doxorubicin dose intensity during the first two cycles of chemotherapy correlated significantly to DDFS when all patients received at least two cycles of chemotherapy were included (P=0.05). The total dose of doxorubicin and cyclophosphamide also correlated significantly to DDFS (P = 0.01 and P = 0.01 respectively) and OS (P = 0.01 and P = 0.01 respectively). Dose intensity of all cycles had no significant correlation to chemotherapy outcome.
After exclusion of patients who relapsed during the chemotherapy or discontinued chemotherapy because of toxicity before having received at least four cycles, a statistically significant correlation between DDFS and leucocyte nadir was still established (P = 0.05). However, total dose of doxorubicin and cyclophosphamide were no longer significantly correlated, and dose intensity of all cycles, as before, had no significant effect on treatment outcome.
For multivariate analyses, age, hormonal receptor status, tamoxifen and radiotherapy treatment, delay between surgery and start of chemotherapy were included in the Cox model, although none of these variables had a statistically significant effect on outcome in univariate analyses. All patients who had received at least two cycles of chemotherapy were included in the analyses. In the multivariate analysis, leucocyte nadir still correlated significantly with DDFS and OS (P = 0.006 and P = 0.04 respectively), while doxorubicin and cyclophosphamide dose intensities of the first two British Journal of Cancer (1997) (Table 1) . Similar correlation of leucocyte nadir with DDFS and OS was seen in multivariate analyses of stage II patients only (P = 0.007 and P = 0.058 respectively) (Figure 1 ). Median DDFS and OS for leucocyte nadir . 4.0, 3-3.9 and < 3.0 (l09 1-' were 80 and 116, 90 and 111, and 126 and 128 months respectively.
DISCUSSION
The interpretation of the dose-effect relationship in retrospective studies is problematic. Redmond et al (1983) was able to demonstrate, in retrospective analyses of 2 years' adjuvant chemotherapy, a significant dose-response effect even in the placebo group because of patients who discontinued therapy as a result of early recurrence or therapy toxicity. Geller et al ( 1990) also demonstrated that differences in disease-free survival (DFS) among patients in different chemotherapy dose regimens could be attributed to early recurrence. Our own results support these findings. The significant correlation between total dose and chemotherapy outcome was lost after excluding early failures who received lower doses because of treatment discontinuation.
One way of overcoming selection bias is to use only the initial dose intensity, as this might be less influenced by patient tolerance and is not affected by subsequent treatment discontinuation. In this study, we established a positive correlation between doxorubicin dose intensity during the first two cycles and distant disease-free survival (DDFS) No statistically significant correlation was found between dose intensity of all cycles and outcome. In contrast to our finding in a previous study, Hryniuk and Levine (1986) demonstrated significant correlation between dose intensity of all cycles and adjuvant chemotherapy outcome. However, the dose intensity was calculated with the minimal duration of therapy (at least six cycles of chemotherapy), and this automatically included early failures in the low-dose intensity group.
An even better way of overcoming selection bias is to correlate treatment outcome with some biological measurement of dose intensity, such as haematological toxicity which is perhaps the most straightforward. The correlation between lower leucocyte nadir and better outcome in the present study support a true dose-response relationship. In fact, a few previous studies of early and advanced breast cancer have also demonstrated a relationship between lower leucocyte nadirs and either a higher response rate or better DFS or OS (Ahmann et al, 1982; Samonigg et al, 1991; Yosef et al, 1993) .
The results of the present study indicate that leucocyte nadir is an easy and reliable biological marker of chemotherapy efficacy. Breast cancer adjuvant chemotherapy with fixed protocol doses seemed to leave a group of patients who had better haematological tolerance with ineffective levels of dose intensity. More individual planning of chemotherapy doses is required. Using leucocyte nadir as a marker for therapy efficacy provides the possibility of establishing an optimal chemotherapy dose intensity for individual patients. The dose intensity during the initial cycles of chemotherapy, in particular, seems to be significant in the optimization of adjuvant chemotherapy.
